{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:14:07Z","timestamp":1793315647022,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8230010085"],"award-info":[{"award-number":["8230010085"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130004"],"award-info":[{"award-number":["82130004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502600"],"award-info":[{"award-number":["2022YFC2502600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Plan of Shanghai Hospital Development Center","award":["SHDC2020CR1032B"],"award-info":[{"award-number":["SHDC2020CR1032B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02507-2","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:27:37Z","timestamp":1766500057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2\/RHOA mutations via JAK3\/STAT3 axis"],"prefix":"10.1186","volume":"23","author":[{"given":"Ting-Ting","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ci","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ran","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"1","key":"2507_CR1","first-page":"47","volume":"70","author":"E Marchi","year":"2020","unstructured":"Marchi E, O\u2019Connor OA. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. CA Cancer J Clin. 2020;70(1):47\u201370.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2507_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ajh.26803","volume":"98","author":"A Ludvigsen Al-Mashhadi","year":"2023","unstructured":"Ludvigsen Al-Mashhadi A, Cederleuf H, Kuhr Jensen R, Holm Nielsen T, Bjerreg\u00e5rd Pedersen M, Bech Mortensen T, et al. Outcome of limited-stage peripheral T-cell lymphoma after CHOP(-like) therapy: a population based study of 239 patients from the Nordic lymphoma epidemiology group. Am J Hematol. 2023;98(3):388\u201397.","journal-title":"Am J Hematol"},{"issue":"16","key":"2507_CR3","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2507_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3324\/haematol.2017.182444","volume":"103","author":"MM Ji","year":"2018","unstructured":"Ji MM, Huang YH, Huang JY, Wang ZF, Fu D, Liu H, et al. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica. 2018;103(4):679\u201387.","journal-title":"Haematologica"},{"issue":"12","key":"2507_CR5","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","volume":"33","author":"Y Watatani","year":"2019","unstructured":"Watatani Y, Sato Y, Miyoshi H, Sakamoto K, Nishida K, Gion Y, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019;33(12):2867\u201383.","journal-title":"Leukemia"},{"issue":"7","key":"2507_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1101\/gad.276568.115","volume":"30","author":"KD Rasmussen","year":"2016","unstructured":"Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016;30(7):733\u201350.","journal-title":"Genes Dev"},{"issue":"7","key":"2507_CR7","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","volume":"120","author":"F Lemonnier","year":"2012","unstructured":"Lemonnier F, Couronn\u00e9 L, Parrens M, Ja\u00efs JP, Travert M, Lamant L, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7):1466\u20139.","journal-title":"Blood"},{"issue":"2","key":"2507_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","volume":"33","author":"JR Cortes","year":"2018","unstructured":"Cortes JR, Ambesi-Impiombato A, Couronn\u00e9 L, Quinn SA, Kim CS, da Silva Almeida AC, et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018;33(2):259-73.e7.","journal-title":"Cancer Cell"},{"issue":"4","key":"2507_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ng.2916","volume":"46","author":"HY Yoo","year":"2014","unstructured":"Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371\u20135.","journal-title":"Nat Genet"},{"issue":"2","key":"2507_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171\u20135.","journal-title":"Nat Genet"},{"issue":"9","key":"2507_CR11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","volume":"132","author":"SY Ng","year":"2018","unstructured":"Ng SY, Brown L, Stevenson K, deSouza T, Aster JC, Louissaint A Jr, et al. RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood. 2018;132(9):935\u201347.","journal-title":"Blood"},{"issue":"3","key":"2507_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","volume":"32","author":"M Fujisawa","year":"2018","unstructured":"Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, Komori D, Gershon P, Kiryu M, et al. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia. 2018;32(3):694\u2013702.","journal-title":"Leukemia"},{"issue":"8","key":"2507_CR13","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1172\/JCI92026","volume":"127","author":"S Zang","year":"2017","unstructured":"Zang S, Li J, Yang H, Zeng H, Han W, Zhang J, et al. Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis. J Clin Invest. 2017;127(8):2998\u20133012.","journal-title":"J Clin Invest"},{"issue":"2","key":"2507_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/CBM-220013","volume":"35","author":"LA de P\u00e1dua Covas Lage","year":"2022","unstructured":"de P\u00e1dua Covas Lage LA, Barreto GC, Culler HF, Cavalcante JB, de Oliveira Alves LB, Nardinelli L, et al. TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients. Cancer Biomark. 2022;35(2):179\u201391.","journal-title":"Cancer Biomark"},{"issue":"1","key":"2507_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01395-4","volume":"14","author":"LA de P\u00e1duaCovasLage","year":"2022","unstructured":"de P\u00e1duaCovasLage LA, Culler HF, Barreto GC, Reichert CO, Levy D, de Oliveira Costa R, et al. Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas. Clin Epigenetics. 2022;14(1):180.","journal-title":"Clin Epigenetics"},{"key":"2507_CR16","doi-asserted-by":"crossref","unstructured":"Bensberg M, Rundquist O, Selimovi\u0107 A, Lagerwall C, Benson M, Gustafsson M, et al. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2021;118(34):e2110758118.","DOI":"10.1073\/pnas.2110758118"},{"issue":"18","key":"2507_CR17","first-page":"2194","volume":"141","author":"J Ruan","year":"2023","unstructured":"Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023;141(18):2194\u2013205.","journal-title":"Blood"},{"issue":"16","key":"2507_CR18","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161\u201370.","journal-title":"Blood"},{"key":"2507_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"2507_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/21541248.2016.1263718","volume":"10","author":"RL Boddicker","year":"2019","unstructured":"Boddicker RL, Razidlo GL, Feldman AL. Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas. Small GTPases. 2019;10(1):33\u20139.","journal-title":"Small GTPases"},{"issue":"15","key":"2507_CR21","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664\u201376.","journal-title":"Blood"},{"issue":"2","key":"2507_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101416","volume":"5","author":"YH Huang","year":"2024","unstructured":"Huang YH, Qiu YR, Zhang QL, Cai MC, Yu H, Zhang JM, et al. Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes. Cell Rep Med. 2024;5(2):101416.","journal-title":"Cell Rep Med"},{"issue":"4","key":"2507_CR23","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1073\/pnas.1608839114","volume":"114","author":"F Abate","year":"2017","unstructured":"Abate F, da Silva-Almeida AC, Zairis S, Robles-Valero J, Couronne L, Khiabanian H, et al. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proc Natl Acad Sci U S A. 2017;114(4):764\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2507_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"NG Azizian","year":"2020","unstructured":"Azizian NG, Li Y. XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol. 2020;13(1):61.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2507_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/1535-7163.MCT-13-0416","volume":"13","author":"Y Cheng","year":"2014","unstructured":"Cheng Y, Holloway MP, Nguyen K, McCauley D, Landesman Y, Kauffman MG, et al. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther. 2014;13(3):675\u201386.","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"2507_CR26","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1182\/blood.2022015451","volume":"140","author":"M Fujisawa","year":"2022","unstructured":"Fujisawa M, Nguyen TB, Abe Y, Suehara Y, Fukumoto K, Suma S, et al. Clonal germinal center B cells function as a niche for T-cell lymphoma. Blood. 2022;140(18):1937\u201350.","journal-title":"Blood"},{"issue":"1","key":"2507_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01649-4","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Guo L, Chen L, Gong B, Jia D, Sun Q. Nuclear transport proteins: structure, function, and disease relevance. Signal Transduct Target Ther. 2023;8(1):425.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2507_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0304-z","volume":"9","author":"JG Turner","year":"2016","unstructured":"Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016;9(1):73.","journal-title":"J Hematol Oncol"},{"issue":"20","key":"2507_CR29","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","volume":"125","author":"ZA Hing","year":"2015","unstructured":"Hing ZA, Mantel R, Beckwith KA, Guinn D, Williams E, Smith LL, et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 2015;125(20):3128\u201332.","journal-title":"Blood"},{"issue":"6","key":"2507_CR30","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2024.01.025","volume":"166","author":"H Wang","year":"2024","unstructured":"Wang H, Yuan S, Zheng Q, Zhang S, Zhang Q, Ji S, et al. Dual Inhibition of CDK4\/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs. Gastroenterology. 2024;166(6):1130-44.e8.","journal-title":"Gastroenterology"},{"issue":"1","key":"2507_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00982-3","volume":"13","author":"M Deng","year":"2020","unstructured":"Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, et al. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020;13(1):148.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2507_CR32","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1182\/blood-2014-08-588855","volume":"125","author":"JS Khorashad","year":"2015","unstructured":"Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, et al. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood. 2015;125(11):1772\u201381.","journal-title":"Blood"},{"issue":"26","key":"2507_CR33","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1182\/blood.2021014238","volume":"138","author":"LC Pinter-Brown","year":"2021","unstructured":"Pinter-Brown LC. JAK\/STAT: a pathway through the maze of PTCL? Blood. 2021;138(26):2747\u20138.","journal-title":"Blood"},{"issue":"18","key":"2507_CR34","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood.2023021789","volume":"144","author":"AJ Moskowitz","year":"2024","unstructured":"Moskowitz AJ, Stuver RN, Horwitz SM. Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs). Blood. 2024;144(18):1887\u201397.","journal-title":"Blood"},{"issue":"6","key":"2507_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","volume":"20","author":"D Fiore","year":"2020","unstructured":"Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20(6):323\u201342.","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"2507_CR36","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828\u201337.","journal-title":"Blood"},{"issue":"10","key":"2507_CR37","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1158\/2159-8290.CD-23-1092","volume":"14","author":"MR Waarts","year":"2024","unstructured":"Waarts MR, Mowla S, Boileau M, Martinez Benitez AR, Sango J, Bagish M, et al. CRISPR dependency screens in primary hematopoietic stem cells identify KDM3B as a genotype-specific vulnerability in IDH2- and TET2-mutant cells. Cancer Discov. 2024;14(10):1860\u201378.","journal-title":"Cancer Discov"},{"issue":"1","key":"2507_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00200-x","volume":"10","author":"Y Ye","year":"2021","unstructured":"Ye Y, Ding N, Mi L, Shi Y, Liu W, Song Y, et al. Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas. Exp Hematol Oncol. 2021;10(1):9.","journal-title":"Exp Hematol Oncol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02507-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02507-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02507-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:27:38Z","timestamp":1766500058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02507-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2507"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02507-2","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study involving human samples and clinical data was approved by the Ruijin Hospital Ethics Committee, Shanghai Jiao Tong University School of Medicine (Approval Number: 2022\u2013317). Written informed consent was obtained from all participants in accordance with the principles of the Declaration of Helsinki. All animal experiments were conducted under protocols approved by the Animal Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Approval Number: RJ2025036).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"533"}}